O-phenyl hydrazinecarbothioate | 25645-96-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-phenyl hydrazinecarbothioate
• 英文别名: Phenoxythiocarbonyl-hydrazin；O-phenyl hydrazinothiocarbamate；O-phenyl N-aminocarbamothioate
• CAS: 25645-96-9
• 化学式: C₇H₈N₂OS
• 分子量: 168.219
• InChiKey: GJBMKXMTTROFGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-bromo-1-(2-phenyl-benzoxazol-6-yl)butan-1-one 、 O-phenyl hydrazinecarbothioate 在 三乙胺 、 对甲苯磺酸 作用下， 以 水 、 乙腈 为溶剂， 反应 1.0h， 以4.1%的产率得到6-ethyl-5-(2-phenyl-benzoxazol-6-yl)-3,6-dihydro-[1,3,4]thiadiazin-2-one
  参考文献：
  名称：

  [EN] PYRIDAZINONES AS GPR119 AGONISTS
  [FR] PYRIDAZINONES UTILISÉS COMME AGONISTES DU RÉCEPTEUR GPR-119

  摘要：

  公开号：

  WO2011138427A3
• 作为产物：
  描述：

  硫代氯甲酸苯酯 在 一水合肼 作用下， 以 乙醚 为溶剂， 生成 O-phenyl hydrazinecarbothioate
  参考文献：
  名称：

  Jensen,K.A. et al., Acta Chemica Scandinavica (1947), 1969, vol. 23, p. 1916 - 1934

  摘要：

  DOI：

文献信息

• A novel type of nonsteroidal estrone sulfatase inhibitors
  作者：Peter Jütten、Winfried Schumann、Albert Härtl、Lothar Heinisch、Udo Gräfe、Walter Werner、Hermann Ulbricht

  DOI：10.1016/s0960-894x(02)00171-3

  日期：2002.5

  structure-activity relationships of our study into a series of thiosemicarbazone derivatives of madurahydroxylactone as potential nonsteroidal inhibitors of the enzyme estrone sulfatase. The most active compound, the cyclohexylthiosemicarbazone, was shown to be a non-competitive inhibitor with a K(i) of 0.35microM. This compound is devoid of estrogenic properties and showed low acute toxicity in the hen's

  马杜拉羟基内酯（MHL）是土壤细菌野紫菜（Nonomuria rubra）产生的次生代谢产物，属于苯并[a]萘并醌类。我们报告的初步结果和我们的研究成一系列的马杜拉羟基内酯的硫半脲衍生物作为潜在的非甾体类雌激素硫酸酯酶抑制剂的结构活性关系。活性最高的化合物，环己基硫代半脲，显示为非竞争性抑制剂，K（i）为0.35microM。该化合物缺乏雌激素特性，在母鸡的可育卵筛查试验中显示出较低的急性毒性。
• Identification, Synthesis, and Biological Evaluation of 6-[(6<i>R</i>)-2-(4-Fluorophenyl)-6-(hydroxymethyl)-4,5,6,7-tetrahydropyrazolo[1,5-<i>a</i>]pyrimidin-3-yl]-2-(2-methylphenyl)pyridazin-3(2<i>H</i>)-one (AS1940477), a Potent p38 MAP Kinase Inhibitor
  作者：Toru Asano、Hitoshi Yamazaki、Chiyoshi Kasahara、Hirokazu Kubota、Toru Kontani、Yu Harayama、Kazuki Ohno、Hidekazu Mizuhara、Masaharu Yokomoto、Keiji Misumi、Tomohiko Kinoshita、Mitsuaki Ohta、Makoto Takeuchi.

  DOI：10.1021/jm3008008

  日期：2012.9.13

  Several p38 MAPK inhibitors have been shown to effectively block the production of cytokines such as IL-1 beta, TNF alpha, and IL-6. Inhibitors of p38 MAP kinase therefore have significant therapeutic potential for the treatment of autoimmune disease. Compound 2a was identified as a potent TNF alpha production inhibitor in vitro but suffered from poor oral bioavailability. Structural modification of 2a led to the discovery of tetrahydropyrazolopyrimidine derivatives, exemplified by compound 3, with an improved pharmacokinetic profile. We found that blocking metabolism at the methyl group of the amine and constructing the tetrahydropyrimidine core were important to obtaining compounds with good biological profiles and oral bioavailability. Pursuing the structure-activity relationships of this series led to the discovery of AS1940477 (3f), with excellent cellular activity and a favorable pharmacokinetic profile. This compound represents a highly potent inhibitor of p38 MAP kinase with regard to in vivo activity in an adjuvant-induced arthritis model.
• HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES
  申请人：Celgene Corporation

  公开号：US20200339559A1

  公开（公告）日：2020-10-29

  Provided herein are Heterocyclic compounds of formula I: and pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein W, X, Y, R 1 , R 2 , and R N are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound, and methods for treating or preventing animal and human filarial worm infections and diseases.